Partnership to improve heart disease therapy


Wednesday, 04 July, 2018


Partnership to improve heart disease therapy

BIOTRONIK, a global producer of cardio- and endovascular medical products, has announced a strategic partnership with GenesisCare, the largest group of private practice cardiologists in Australia, to enhance outcomes for Australian cardiac patients.

Over the course of three years the partners will initiate interdisciplinary research projects focusing on better data sharing, care pathways and integration, as well as tracking outcomes. BIOTRONIK will contribute its vast technological knowledge to the partnership, while GenesisCare has established systems to monitor and measure patient outcomes.

“With the necessary technology and know-how, we aim to improve patient outcomes with more responsive, personalised and appropriate care,” said Dr Stephen Worthley, Executive Manager at GenesisCare. “This could lead to fewer adverse events, earlier detection of preventable problems and reduced need for hospitalisation.”

Cardiac patients can benefit from this new approach in terms of fewer hospital visits and complications, and lower mortality. This will ultimately translate into lower therapy costs, benefiting patients and health insurers.

“Our partnership aims to overcome obstacles we face when acting alone,” said Jan Ewert, Managing Director of BIOTRONIK Australia and New Zealand. “We look forward to collaborating with GenesisCare to work towards a common goal: redefining how patients receive the best possible care.”

Image credit: ©stock.adobe.com/au/verinize

Related News

UNSW medical psychology researcher wins Harkness Fellowship

Associate Professor Nadine Kasparian has won the 2018–19 Harkness Fellowship in Health Care...

Identifying gut microbes linked to mammalian evolution

Scientists have made a key advance towards understanding which of the trillions of gut microbes...

Protein found to help limit inflammation

Researchers have uncovered a previously unknown role for the cholesterol regulatory protein LRP1,...


  • All content Copyright © 2018 Westwick-Farrow Pty Ltd